Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(17%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
1
17%
Ph phase_1
2
33%
Ph phase_4
2
33%
Ph phase_2
1
17%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (33.3%)
Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 42 (33.3%)

Trials by Status

completed467%
recruiting117%
terminated117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_1

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

NCT06834035
completedphase_1

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

NCT07025577
completedphase_2

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

NCT04175522
completedphase_4

Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease

NCT04003844
terminatedphase_3

GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

NCT01315496
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06834035Phase 1

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Recruiting
NCT07025577Phase 1

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

Completed
NCT04175522Phase 2

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

Completed
NCT04003844Phase 4

Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease

Completed
NCT01315496Phase 3

GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

Terminated
NCT01524939Phase 4

Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6